CA3110233A1 - Utilisation de chloroplastes pour la production d'oxygene dans des cultures cellulaires - Google Patents
Utilisation de chloroplastes pour la production d'oxygene dans des cultures cellulaires Download PDFInfo
- Publication number
- CA3110233A1 CA3110233A1 CA3110233A CA3110233A CA3110233A1 CA 3110233 A1 CA3110233 A1 CA 3110233A1 CA 3110233 A CA3110233 A CA 3110233A CA 3110233 A CA3110233 A CA 3110233A CA 3110233 A1 CA3110233 A1 CA 3110233A1
- Authority
- CA
- Canada
- Prior art keywords
- chloroplasts
- media
- oxygen
- million
- mammalian cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003763 chloroplast Anatomy 0.000 title claims abstract description 198
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title claims abstract description 78
- 229910052760 oxygen Inorganic materials 0.000 title claims abstract description 78
- 239000001301 oxygen Substances 0.000 title claims abstract description 78
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 17
- 238000004113 cell culture Methods 0.000 title description 5
- 238000000034 method Methods 0.000 claims abstract description 60
- 210000004962 mammalian cell Anatomy 0.000 claims abstract description 30
- 239000001963 growth medium Substances 0.000 claims description 43
- 239000000463 material Substances 0.000 claims description 19
- 230000035899 viability Effects 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 8
- 210000000130 stem cell Anatomy 0.000 claims description 4
- 230000004069 differentiation Effects 0.000 claims description 3
- 230000012010 growth Effects 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 19
- 230000008569 process Effects 0.000 description 15
- 241000219315 Spinacia Species 0.000 description 11
- 235000009337 Spinacia oleracea Nutrition 0.000 description 11
- 239000002609 medium Substances 0.000 description 7
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000029553 photosynthesis Effects 0.000 description 5
- 238000010672 photosynthesis Methods 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 241001185310 Symbiotes <prokaryote> Species 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 230000014306 paracrine signaling Effects 0.000 description 2
- 230000009919 sequestration Effects 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108020004998 Chloroplast DNA Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 238000013406 biomanufacturing process Methods 0.000 description 1
- 238000010352 biotechnological method Methods 0.000 description 1
- 238000013452 biotechnological production Methods 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 210000004920 epithelial cell of skin Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000006545 glycolytic metabolism Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 230000019432 tissue death Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/71—Oxidoreductases (EC 1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
- C12N2529/10—Stimulation by light
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne également des procédés et des systèmes pour augmenter l'oxygène destiné à être utilisé par des cellules de mammifère. Dans certains modes de réalisation, un procédé d'augmentation de la concentration en oxygène pour des cellules de mammifère consiste à cocultiver des chloroplastes dans au moins une plaque à puits avec des cellules de mammifère dans un milieu et à augmenter la production d'oxygène par exposition des chloroplastes à la lumière.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862734314P | 2018-09-21 | 2018-09-21 | |
| US62/734,314 | 2018-09-21 | ||
| PCT/US2019/052231 WO2020061500A1 (fr) | 2018-09-21 | 2019-09-20 | Utilisation de chloroplastes pour la production d'oxygène dans des cultures cellulaires |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3110233A1 true CA3110233A1 (fr) | 2020-03-26 |
Family
ID=69888943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3110233A Pending CA3110233A1 (fr) | 2018-09-21 | 2019-09-20 | Utilisation de chloroplastes pour la production d'oxygene dans des cultures cellulaires |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP3853346A4 (fr) |
| CA (1) | CA3110233A1 (fr) |
| WO (1) | WO2020061500A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116585530B (zh) * | 2023-05-05 | 2024-02-02 | 暨南大学 | 一种高效产氧的叶绿体复合水凝胶及其制备方法与应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2389958A1 (fr) * | 2010-03-22 | 2011-11-30 | Technische Universität Klinikum Rechts der Isar | Utilisation de bases photosynthétiques dans l'ingénierie de tissus |
| WO2016037010A1 (fr) * | 2014-09-03 | 2016-03-10 | Symbiox, Inc. | Substances cellulaires photosynthétiques et leurs procédés d'utilisation |
| US10883080B2 (en) * | 2015-06-25 | 2021-01-05 | Tokyo Women's Medical University | Method for culturing animal cell composition, method for producing animal cell composition using same, and animal cell composition |
-
2019
- 2019-09-20 WO PCT/US2019/052231 patent/WO2020061500A1/fr unknown
- 2019-09-20 EP EP19861733.4A patent/EP3853346A4/fr not_active Withdrawn
- 2019-09-20 CA CA3110233A patent/CA3110233A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3853346A1 (fr) | 2021-07-28 |
| EP3853346A4 (fr) | 2022-06-01 |
| WO2020061500A1 (fr) | 2020-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bédard et al. | Innovative human three-dimensional tissue-engineered models as an alternative to animal testing | |
| Bhat et al. | Prospectus of cultured meat—advancing meat alternatives | |
| EP1747264B1 (fr) | Systemes de culture tissulaire et organique multicellulaires | |
| US20100035327A1 (en) | Use of rice-derived products in a universal cell culture medium | |
| CN101914495A (zh) | 用于体外大量扩增毛囊干细胞的培养方法 | |
| EP2446892A2 (fr) | Cellules souches isolées adultes pluripotentes et leur procédé d'isolation et de mise en culture | |
| Takahashi et al. | Harvest of quality-controlled bovine myogenic cells and biomimetic bovine muscle tissue engineering for sustainable meat production | |
| CN112190592B (zh) | miRNA在制备防治骨关节炎药物的应用、miRNA高表达的外泌体和应用 | |
| US20210395694A1 (en) | Method for promoting production of exosomes and/or extracellular vesicles | |
| CN102102090A (zh) | 一种非接触共培养诱导干细胞体外定向分化的方法 | |
| CN109112101A (zh) | 一种成纤维细胞培养基及其应用 | |
| Shoushrah et al. | Sinking our teeth in getting dental stem cells to clinics for bone regeneration | |
| CN111534477B (zh) | 小鼠肺组织原代上皮干细胞球培养方法 | |
| US20210123013A1 (en) | System for cell culture in a bioreactor | |
| Mengistie | Lab-growing meat production from stem cell | |
| Grabowska et al. | Adipose tissue-derived stromal cells in matrigel impact the regeneration of severely damaged skeletal muscles | |
| Gradišnik et al. | Advanced bio-based polymers for astrocyte cell models | |
| Noor et al. | Newer trends and techniques adopted for manufacturing of In vitro meat through “tissue-engineering” technology: a review | |
| CA3110233A1 (fr) | Utilisation de chloroplastes pour la production d'oxygene dans des cultures cellulaires | |
| CN105754943A (zh) | 一种裸鼹鼠海马神经元培养方法 | |
| JP2006314759A (ja) | 移植用軟骨組成物 | |
| CN105963795A (zh) | 一种基于胶原制备组织工程表皮的方法 | |
| CN104877954A (zh) | 一种干细胞壁龛及其制备方法与应用 | |
| Singh et al. | In vitro meat-the start of new era in meat production | |
| CN114703126A (zh) | 肌肉干细胞分离提取及新型水解物培养体系及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220926 |
|
| EEER | Examination request |
Effective date: 20220926 |
|
| EEER | Examination request |
Effective date: 20220926 |